Public biotechnology 2004- the numbers

Article Abstract:

The Nature biotechnology annual survey of biotech companies whose shares are traded publicly on stock exchanges indicates that 309 firms generated collectively almost $47 billion in revenue for 2004 and their additive R$D outlay amounted to about $16 billion an increase of 18% over 2003. Though biotech financials are improving, with rapidly increasing revenue and improving profitability, several factors on the regulatory, scientific and intellectual property fronts could affect future growth.

---

Public biotechnology 2005- the numbers

Article Abstract:

An annual survey of biotech companies whose shares are traded publicly on stock exchange indicates that 404 firms generated collectively more than $63 billion in revenue for 2005. In 2005, total net losses for these companies shrank rapidly from $3.6 billion to less than $1 billion.

---

Public biotechnology 2003 -- the numbers

Article Abstract:

Biotech financing in 2003 outpaced both 2001 and 2002 levels as the publicly traded biotechs raised $13.6 billion from all sources in 2003 as compared with only $7.4 billion in 2002. The biotech indices for both Nasdaq and American Stock Exchanges soared up about 45 percentage.

Legal issues & crime, Sales, profits & dividends, Forecasts, trends, outlooks, Security brokers and dealers, Securities & Commodities Services, Securities, Commodity Contracts, and Other Financial Investments and Related Activities, Company legal issue, Forecasts and trends, Investigations, Securities industry, Market trend/market analysis, Company sales and earnings, Company earnings/profit, American Stock Exchange L.L.C., Nasdaq Stock Market Inc.

Similar abstracts:

• Abstracts: The return of the biotech scorecard. PEGing biotech growth. How do your stocks really perform?
• Abstracts: Breaking with the bank. Facing the CLS liquidity challenge. Firms fail to follow the money
• Abstracts: Client expense accounting becomes more complex. Planning to propose in '06-part II. Home office deduction revisited
• Abstracts: M & A 2004 heading for a record year? Portugal's banks fuel economic recovery
• Abstracts: Rainbow biotech-South Africa's emerging sector. Margaret Atwood

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.